The Norwegian oncology developer BerGenBio ASA is making an initial public offering of its shares on the Oslo Stock Exchange in order to support development of a Phase 2 compound targeting three cancer indications. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
